After SunTrust Robinson and Piper Sandler gave Adverum Biotechnologies (NASDAQ: ADVM) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Gbola Amusa reiterated a Buy rating on Adverum Biotechnologies today. The company’s shares